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i\dolesccuce and contraception 
Donald .E G:reydanus\ MD, 
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Hatim A Omar~ l\1.0~ 
and Colleen B Dodkh, MD 
Department ofPed)(ltric and Adolescent Medici.11e, 
Western Michigan UrJversity School of Medicine, 
KaLnnazoo, lVIichigan and i\dol,:scent Medicine and 
Young Parent Programs, J422 Kentucky Clinic, 
Department ofPedmtrics, Kentucky Children· s Hospital, 
l.Jnivcrsity of Kentucky College ofMedicine, 
Lexington, Kentucky, Un.ited States of lunericn 
' Co:rrespondence: Profess:)r Don<il<.l E Grcydanus, MD, 
Uepmtmcnt of Pediatric and Ad.nlegcent Mcdicine, 
Pediati"ics Program Director iltld Feunding Chir, West:;n: 
Michigan Univ,~rsity Sdwol ~lf :11-'fedbne, l ODO Cak!and 
Drive, Kalama:-:no, MI 49008-l2R4 Cnited States. E-tnail: 
donal d.g;-cydanu ~@mc:d. ·wmich. ed u 
'11Ie age of ado{escencc: is· the bJ11e ·vvhcn mos·1 adolescf}nts 
in the world beCQme sexually active with resultant millions 
of pregnancies and sexucdly transmitted disease~. This 
paper considers methods of contraception fbr ll-Jese 
adolescents, inchJding oral contraceptives, transdt.;tmal 
contraception, tJ}in.i"-pi!is, intrnvagina1 r3ng~ h1jectab1e 
contraGeplion, intrauterine devices, barrier contraceptives, 
implants; l:'..nd 0thers. It is impm1ant for clinicians qrhg for 
sexually active ym;th t.o provide informatl011 regarding 
c.ontraGeptie:n and appropriate contraceptjve prescriptions. 
Key;>.·ord&: Adoles~;t:rx:e, contraception 
In troduetion 
The median age of first intercourse in the United 
States, \\7estern Europe, Eastetn Europe (Ukraine), 
Eurasia (Russia), and other parts of thl: world is 16 
years of age, with man:;' youth having multiple sexm:J 
partners. CEnicians caring for adolescents should ask 
about possible coital behavior and provide effective 
contra(:eption to those youth continuing to be sexually 
active without in.hmt of becoming pregnant (1-23). 
Table 1 lists questions helpful to ask when discussing 
contraception with adolescents "particularly i.C they 
are sexually active. 
A number o1 effective and safe ccntraceptivc 
methods (see Table 2) are ayailabk fol the sexually 
active adolescent who v-:ishes to avoid pregnancy. The 
most effeGtive tnethods of contraception indutk 
abstinence, comb!r;ed oral contraceptives (24}, 
tnmsdcrrna1 contra;,:eptive patch (Ortho Evra®), 
vaginal contraceptive dng (NuvaRing@)~ progesbn-
releasing implant (lmplancm®), lUDs, and 
intrarnuscular medroxy-pwgesterom: acetate (Depo-
Provcra, DMPA): these method~ have pregnancy rates 
;mder l/100 woman years ofuse (see Table 3). 
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Tabk l. Questifms for Adol~~cents Sec.!iing C\lntra~eptio;n 
.-····-··~... ··-·~·~·-·-··-·_._ ..... -.. -.,.,---:--------.. ................ -.......... _ ..... ...-.... ~----~--------~ 
W1Jat :methods have you used before, if any? L 
2. 
3. 
4. 
Did )lOU have <my problems with your previous method? \\1lat did you like/dislike? 
Do you have any concerns about the diffenmt methods of contraception? 
If your friends use contraception, what comrnertts have :hey made? 
S. \ViE you he able to use these methods correctly? Which ones? 
6. Is your W(;;ight of concern to ym1'? Ihve you been m· are you now dieting? 
7. Sorne methods may lead tc unplarmed, irregulat bleeding. Can you de~•l vvlH1 that? . 
8. :r~ve -~m;_ het.rd about any problems with the pill or ether methods, snch as possible weight gain or i 
~~~: I 
9. Ate you 2.\li:tre of minor side effects that the pi!! may cause? j 
10. }?.~Y~"?.I_l ... ~~Y.~ .. 'l!J.~stkms l huve not at~~-~~~<:1,:~~-? ....................... _. ························-·-··························-·-·-···' 
Table 2. Contrz.cepl:ive l\'1ethods 
r~·····----------·---~--------------~--------·················•••••••••·······------~--~-------·-~-~-~------------~----------·-····························---~----------·-·-·---------·····-----~--------------------~ 
i Abstinence i 
i Rhytlmt method of contraception (periodic abstimmc:e} j 
i CaleJ!dar i 
Ovulation method l 
Symptothermal 
Postovu1ation 
Oral Contraceptiv;~s (Combined) 
Transdermal Contrac~ptive Patch (Ortho Evra) 
Vaginal Contraceptive Ri'lg (NuvaRi:ng) 
Mir;i.pills (Progestin-only pill5; POP::) 
Emergency contraceptives 
Barrier contmceptives 
Diaphragm 
Vaginal contraceptive sponge 
Cervical cap (Pr.entif Cavity~rim®) 
Female condom (ReaHi:y~)) 
Vaginal spem1icides 
Male condoms 
Injectable C<mtraceptives 
Depo-Provera(fp 
Lv.nt~lleCJ,<) 
Ir.tnmtcrir: e Devices 
Progesta~a;rt@ IUD (with progesterone) 
ParaGa.rd(E>(Copper T380A IUD) 
Min~na@ (!l.lD with levonorgestrel), 
Implants 
lmplanon 
Norplant (no hnger availab.le in the US) 
Steri1iz.ation 
.Fernak 
l\,laie ( va~cctomy) 
L CoiJu;; i~_!_{:.~-~-lJ!J::~_s_· ---·-·-·-·--·-·-·---~-·-·-·-·-·-· 
Uni{ntunately, the difference m contraceptive 
effectlvenes~ between perfect use and typical use 
leads to n:d lEons of unin.t(~nded pregnancies each year. 
Perfect use is defined as correct~ consistent, and 
continued use of a method chosen by the sexuaUy 
----·-·-·-·-·-·-····-··-:---
active patient. The less patient-dependent a method, 
the cioser the typkal us~ge i.s tn the perfect usage. 
Tims, methods such as the implant, DMPA, and TUDs 
hav~ typical usage that is viriually equal to perfect 
usage, and the in.travaginal ril'1g and transd~crmal patch 
h;tve b~Ut~r rypica1 usage than OCPs, 
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Table 3. Effectiven ess ol' Methuds 
... M.~.!~!.~~~~ .............................................. =~~~:-------------·r:p~-~i~~i .. u~~----............... ...... 1 TvJ;ic-;·:·--u;~--... ----·------------------------------.... : 
. .. .................. -t-... -" • ' " : ! 
OCP i >99% , 95% 1 Ottho Evra --------------'f";(jg~~- - -- - -------· ....................... __ . ___ =Tii99o/~-----.................................................... l 
--N~-~a'Ri~;; ............................................................... , ... ?.~.:2-Y.-~ .................................... ~~---------....... ~-~~-~~~t1:C~~~==-~-=--=~---............. ....... =:~ 
.. .P.M:~:~........................................................ : 99..:Lt? ... --- ------------------------..... i.2 "'· ! .v.: J 
Mir£.1?.~...... .......... .. ............................. 1..~-~:-~!.:'c.............. ...... ................. 99. 9'Y.o... ......................................................... J 
... t~~~.S!r.r:2. ________ ................................ ! 99.4% ........................... , .. 2.9.2% . i 
Condoms _ ..................... 1 --!t~~-;--------------·-----------·--_-................... · ....... >. ··8·1·-~-~-··_;' __ ~_Y. __ ;_._*_-__ :~~:· ... :: .. :--.:-................................. _~--------~-~ 
. .!~~B!~~~~.:. ....................................... __ ...,. _ __ ..;.........:.:.c::..:...::~----- , --- ---- .. .. 
*post mark~tir.g P~ari index o1'0.024 
TaMe 4. Method~ to DeHver Steroids 
r-c-.- -------- ---·----·----··- ·----··--···--· P{(l~ 
Patch 
Injeetablcs 
Implants 
V::;gina1 Rings 
Hormone-releasing lUDs ---------------............ -------' 
Tabte 5. Advantages ofNewn Contraceptive Methods 
t~-r~fib~-ti~~~-~~~-~~-----------------------~----~- -------
' ,., ~ th d ; ; .::~nsy ,,or ,e·a o.escent to usc 
! In.creased number ofoptions 
! Improved compliance 
·_i,: Low honnone doses !,':. 
. Cm1tinuous low levels ofho!mones 
Reversible :....;:;.::;..;..==:;.._-- -----·----------------------------··' 
The barrier rnethods (male condoms, d iaphragms, 
cervical caps, vaginal sponges, female condoms and 
vaginal spermicides) arc not tyvically recommended 
as the ~ole contraceptive method for adolr~'>cents, 
unless they are mature and motivated enough to use 
them; ev(;n then, pregnancy raks are higher than \vith 
th(~ methods identified above as the most effective 
ones. 
()ver th(~ past 20 years_~ a n-;.H11ber of ne_\\ter 
contr;i.ccptivc methods have been approved in the 
United States by the Wasbngton, DC .Federal Drug 
Administration; these include emergency 
contraceptive::,; (Preven® , Plan B®), l)epo~P:·ovcra®, 
the ce:vical C;3.p, Lu.nell t:@ (injectable contraceptive 
wi1b estrogen), Mir~na® (an IUD \vith 
levonorgestrel), the contraceptive patch (Ortl.HJ 
Evra®) cand an intravaginal rrng(NuvaRi.ng®). Over 
the past I 5 years, research has developed various 
ways of contracepiive steroid release (Table 4), 
p(c)chidng a number of potential advantages. (Table 5). 
Atter OCPs were developed in the 1960s, the 
empha-~ is has been on having plU formulations that 
have reduced estn1gc:n and progestin dosages along 
with the development of phasic and extended dosing 
regimens as well as the above tnentii)twct newer 
hormone delivery methods. 
This chapter reviews some 
methods of contraception. Figure 
of these important 
1 lists frequency of 
contraceptive use by sexually active adolescents in the 
lln.ited States. 
Oral contraceptives (OCPs; COCs) 
One of the main contraceptives for several 
decades has been the combined oral :.;ontrac:eptive 
(COCs), containing synthetic estrogen (llSua.lly 
ethinyl estradiol THE], occaslonaHy mestranol) and 
synthetic progesterone (Table 6) (l-7). 
The mechanisms ofactic}n for the cCJrnblncd birth 
control pill (OCPs or <;OCs) to prevent pregnancy 
include inhibition of ovt\la.tior:, cervical mucus 
thickening, endometrial atrophy, and tubal transport 
changes. When discussing OCP~ with adolescent'>~ lt 
is helpful to note the many benc.fits and uses of these 
pills, as listed in Table 7. OCPs are usual1y available 
as 28 oay packs which contajn 21 days of ac:ti vc pills 
containing consistent steroid dosages (mono -pha~ic) 
and placebo ri11s for the last 7 days to allow the 
adolescent fo continue with oi1e pill a day. 
Variations are being developed, suc.h as having 
only two days of placebo fot each 28 day cycle and 
extended cycles. 
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/\H n!"~:~~~r--:n~~ (k:4 f-~rn~::·:{~:-~ 
f)~::r:,n:-t{;\t~ :.~f )t) n~d ~.ex~.:~~~ 
;;· ··: h~n:.-:Jl.:rtl.& ~-~ -~ -~ : :·i~:~ -:J ~nc:ntf's 
)<~~-~t t>:·~(~H·:r~<:~~i 
~ ~--:-~~;-r: ~:)~:-::::":_ ;_ c~ nd c-::;~:·;· .. kH-:"'~J 
W~~§~r (~;-·,·:~! (Xyitf.t!{X-:~ >~!V(; ~_PWJ 
N~--~ rr: ~ti1~F;f 
Figure l, Contraceptive use among never-married female adoJesce;1ts 15-19 years of age who had sexual intercourse ht the 
past 3 months, by specif1ed method used at last int10rcourse and race and Hispanic origin: 1;nitcd Statt;s, 2002. 
Multiphasic piils have also been developed which 
contain StGrojd dosages that vaxy through the month 
(bi- or tri-phasic). There 15 no evidence that 
multiphas[c pills provide any benefit ever :-:;:wno~ 
phasic formulations and are often more expensive. 
There is also no evidence that one OCP brand is better 
Jban another:, only that an individnal adolescent may 
prefer or tolerate one brand over another. Gcnctal!y, a 
pill with bet'.veen 20 meg and 35 meg of EE is. 
selected. While effic:acy appears m be the ~arne, pilh; 
containing 20 meg or less of EE have been shown to 
have a greater rate of irregu1ar bleeding than higher 
dose piils. 
Some kmaJes benefit from extending their 
menstrual cycle to rcduc~ the number of yearly 
menstrual periods. This method can used. in those 
lJ[Piihg problems worsened by their menstrual periods, 
such as those with epi1epsy, headaches, menorrhagia, 
premenstrual te11sion syndrome, mm dcfkiency 
anetnia, endometriosis, coagulation disorders, those 
rece!ving anticoagulation, athletes wishing to avoid a 
cycle during an important sports event, and vthers. 91 
day packs an: cw::n.mtly cpmmen:ially available 
{Seasonique@, Seasonale®, LoSeasonique@), 
1\iorgestrel 
i.Vorethindrone 
l'-!'oreihindrone acetate 
Ethynodiol aatwe 
Gestodcne 
Levmwrgest.rel 
ll•orgesmnate 
De.~ogestrel 
Drr'Jspirenot<e 
:· 
:· 
: 
:· 
,. 
,. 
,. 
,. 
=· · 
,. 
,. 
,. 
,. 
,. 
> 
' > 
' :--
' >· 
' > 
' >· 
' >· 
<· 
>· 
' >· 
' >· 
' >· 
' :- -
' :- -, . 
>· 
>· 
' >· , . 
>· 
' >· 
' >· 
' >· 
' >· 
< · 
>· 
' >· , . 
>· , . 
>· 
! 
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Tah!e 7. Misst:d Orni CQntraccptivc l"Uh; 
---f~~: Do~art of PHI : Number of nilk-~n~sse·d·----------------------------------------------·----
--~---------·-··-M ....................... ~ .......................... J._______ . . ......................................................................... .<· 
30-35mcg ! 1-2 piils missed: 3 or more pii!s missed*: i 
i Ta.l(e last missed pill immediatdy and Take last missed pill imrnediate!y and c~intimw ; 
' ·on~i·1·•a norma! pi" ~ak:no· scheudul ·· nort!tal pill -taking schcudldc. Discard other l 
I ~actL~; ~l;tl;od n;:~~l~H~c·d~l. . . t;. ~1!~~~~1;i~~thod need~~d for 7 days. I 
!----------+! ---- ---- I Consider EC. ! 20mcg or less 1 oi!t mi.tsed: -·---·-................... ____ .... r
1
· .. T;;;.--;;;~~~:;,-pills missed* : -i 
T~k~ J_ast misse_d pill irt~ediately and Take _ l-ast, ~>is.se_d pil.l in:nued iat~ly and c~ntinue ! 
contmue nonnal p1l1-takmg scheudt1le. , normal pll;-mkmg scbeuduh: . D;scarcl on1er i 
Back-up method net needed. I missed pHis. i 
! Hac:k--up method needed for 7 days. i 
I Cons1der EC. _____________ _! 
*Ifmissed''j)iii'S'"Cc;-~-;:- during 3rd ~~~~k~-!inf~h active pills, disctmi p!accbos, and start new pack. 
Table- fi. Use of Ond Contracepti-v~s 
to )Han age Val"iou~ Disorders 
A.cne vulgaris 
~------------------------! 
Coagulc>pathi c:~ (Aritkoagulatlon Therapy) 
Decreased risk of ectopic: pregn~mcy, ovarian 
and endometrial cancer 
Dysmenorrhea 
:Epilepsy 
! Endometriosis 
i 11eadaches 
smenonhea due to .:ating disorders, 
exen:ist:, stress 
Iron Def1ciency Anemia 
Menorrhagia 
Polycystic Ovary Syndrome (PCOS) 
I 
i 
i 
i 
·; 
i 
i 
i 
i 
Prematr:.re ovarian faih;re/Tumer syndrome 
Pr<~menstrual Syndrome (FM:S)!Ptcmcn.stmal T r:ension 
Syndrome (PTS} 
! Rheumatoid .Arthritis . 
~--.--.--.. ···- ····-·······-···············"""•"""•"""•""'•"""···--·--- ---- -. ...................................... . 
OCPs may be initiated a<:cordin g to th1'ee differe11t 
schedules: Quic~ Start, First Day Stan and Sunday 
Start. .A urine pregnancy te:st may be performed if 
patient ha:. 1lad Ut1protected sex since last menses, <md 
should be repcatc<t if r1ext men.&es is missed Qt there 
are other c.onccrns for pregnancy. Emergency 
contraception may be considered if unprotected sex 
has occurred in the last 5 days. 
For the Quick Start method, the patient should 
take the ilrst pill immediately and back~up 
contraccptkm should be used for 7 days (24 ). Quick 
Start may improve comp1iance, decrease confusion, 
and provide near irnrnediatc contraception. OCPs can 
also be started on the first day of the next menses and 
no back-up method iii ne,~ded. Lastly, they may be 
started on the Sunday after the next menses, although 
h•~ck- up contraception is needed for 7 days with a 
Sunday Start. 
This may cause connJston, difficu.hy witb. 
\Veekend refills, and delay in initiation, especiaLly in 
won'len with irregular menses, Table 8 provides 
instruction on mari.agement of missed pills. The 
sexually active adoh:sce~1t should be instru(.;ted that 
OC.Ps (COCs) do not preve.nt sexually trans mitted 
diseases, ar.d thus, condoms, are also recommended. 
Contraindications to OCPs/COCs 
Counseling sexual!y active youth about OCPs 
involves discussing conditi.ons that may present 
increased risks for tl-10 adolescent. The World Health 
Organlntion (Wl:!.O) has published guidelines for 
me(.!ical digibiiity to hdp in this f.ndeavor (Table 9). 
'Females in WHO Cat(:;gor:y I have no restr:iGtions 
to using OCPs, while those in \VHO Category 2 have 
some increased medical risk. Hcwcvcr, OCPs and 
other combined hormonal contraceptives should still 
be considered fnr those in Category 2 as the. I'isk '-"~f 
pregnancy may outweigh the medical co11cerns. 
Females 1n WHO Category 3 have such an 
increased risk that they are not placed on OCPs uD.less 
there is no O"thet available, effective, contraceptive 
agent. FinaHy, those in 'NHO Category 4 are not 
placed on the OCP because the medical risks are too 
great. 
~ 
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-------------------------------------------------------------------------------------------------~---------------------------------c~tegory One (Nu Restrictiom>) 
Antibiotics 
Benign breast disea:-;;~ 
Benign ovarian tumors 
Cervical ectropion 
Dysmenorrhea, 
Endometnosis 
Epilepsy 
Family history of breast cancer 
Gestational trophob!a~tic di~easu (benign or malignant) 
Headaches (mild) 
Histmy of ectopic pn~g11ancy or abortion. (posi abortion after first or secDnd 
trimester), 
History of gest&tional d~abetes 
Increased S TD risk 
Iron deficiency anemia 
lrreguiar menstrual bleeding 
Obesity 
Ovarian or endometrial cancer 
Past pelvic surgery 
Pelvic inflammatory disease 
PGstpartum at or over 21 d<Jys 
Thyroid disorders (as hypo/hyperthymidism, simple goiter) 
Varico&e veins 
Various infectiGns :malaria, tuberculosis, others) 
Sexually transmitted diseases 
Viral hepatitis carrier 
Category Twu (Caution) 
:Cervic..a} crtncer 
Diabetes mellitL!s (ur.comp1icated) 
Headaches (severe and ifthey start after beginning OCPs) 
Hypertension at 140-159/J 00-1 09 mrn Eg 
M~ior smgery without prolonged immobilization 
Migraine headaches without focal neurologic involvement. 
Patiems who hav~ a hard time taking the OCP correctly: 
d.wg or alcohol abuse 
mental retardation 
persistent history as poor OCP takers 
severe psychiatric dsorden; 
Sickle cdl disease or sickle C disease 
Undiagno~;~,:,d breast mass 
Category Th:ree {D~uaHy no OCP given) 
Gatlbladdcr disease 
Lactating (6 weeks to 6 months), 
tess tha,n 21 days postpartum 
Mcdic:::.tions t.hat interf~re with OCP efilcacy 
Undiagnosed abnormal vaginnliuterine bleedbg. 
Categ·t1:ry f.o1c~r (OCP contraimlicaterl} 
Bn.:a~>t cancer 
Ccrebrov;~scuiar accident (adlve or history) 
Comp!icated __ ~E::!-Ef.~~£al heart disea~r:t'-"~-~tQ.P~.!!,t_~~-~:~ExJlYOcrtension , atrial 
>::::;::::'" 
:·:::.:;::: : 
.· ·. : .~ 
:. :: ::::~·: .. 
L. 
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f~-~---~-~-fibriliation·o~:-hist"(;;::::·of~-sub acute bacteria 1 en Joc_G_l_'ri-. i-ti-:-.)-------------------------------------------------------------------------------------------) 
l Coronary {or ische~ic) heart disease (active or bi;t~)r~)-, i 
l Deep vein thrombosis or pulmonary c~1bolism (activ~ ofhi."tmy\ i 
Diabetes mellitus ( complicabl wii~1 retinopathy, neuropathy, n-e~luop:~thy) i 
Headaches (including migraine headaches) with f()cai neurologic symp\oms i 
Hypertension (severe: ( J 60-'-/ l J 0+ mm Hg or with vase-dar eomp lications} i 
Lactation under 6 ;vceks I ! 
Liver disease (inducting Ever cancer. benign heeatic adcrwma. active viTal 
hepatitis, severe cirrhosis) ... · , 
! 
l 
Pregnancy, complicated 
---------------~~~~-')J'I£J.~.'?.~-~:~~8.!E:~l'?.~~:-~~--~~-~r-~:.l_1jtiE_s __ ~.~~J/?E.f'.l_-~?.~~~!'.g~-~:.i_f!:1mcJbiti;ation 
*lhcd with pcnr;issiDn ±rom Grey dan us DE: Contraception. ln~ Course Manli.aCfo·"'. r.::....:A..:.d:.:.:o..:.Je::...s_c_e_n _ t_H_l_Cf-d~tt-1.-E-·-d-s:_D_• -E-. -G-Jr_e_y....JdamJs, 
DR Patel, H Pratt, S Bhave. Ch. 20:309-324; 2002. . . . 
Cardiovascular risks and OCP!S 
If the adolescent has had a venous thrombcisi~ in the 
past, OCPs arc contraindicated (25-27). Venous 
thronibosis (VT) risks are greater in the adolescent 
and young adult female than risks for arterial 
thre:mhosis, Morbid obesiLy is a weU-kno>vn risk 
factor for VT, though the an:wunt of increased risk in 
tbc otherwise healthy adofesccnt is not lmown. Most 
adolescents \Vho develop a VT do not have 
idcntiftable dsk fq,ctors. S~rcedng questions fm~ 
adolescent~ seeking OCPS in regards to VT are Ested 
in Table H), 
i 
Tijh]e 10. Qut.~jinn.§ abont persun~llfamily bhtory 
~1f thmmboemhoHsm 
l 
'· 
3. 
Have you or a dose family me1nber 
(including uncles/aunts) had blood dots in legs 
or lungs? 
Have you or a cio~>e family member been 
hospitalized for blood clots in legs/ltmgs? 
Have you m a close family member taken 
binod thinners? 
! ! 4. Under what circu:nstanccs did the clot fom1? i 
' : L__j~.:.,_i£:_ during air trave!) _____ , ___________________ _] 
Table 11 lists risk factors for thrombosis. Death 
from cardiovascular disease {arterial and venous) can 
occur among 20--24 year old. femaks at 2-6 per 
million per year. 
Thus, death from the OCP is a small, but known 
risk, though the risk of death from pregnancy is much 
greater. The OC? should be stopp~d if the adoh.!sccnt 
has a condition requiring prolonged bed rest, as with 
major surgery. 
Smoking shou1d be discouraged in the adolescent 
but is not a reason by Hself to avoid OCP::;. Blood 
presstw: can increase in those on OCPs and should be 
monitored. E there is. a personal or family history for 
increased lipids, the OCP is permitted if the ]o<,v 
density lip<,.)protein range is under 160 mg/dl or the 
trjglycer1des under 250. Other guidelines ;nay be used 
by the clinician if these guidelines are not accepted in 
one's region. 
TaMe lL llisk Factors for Tbomhosis 
r--r~:e;~~iincy---------------------------------------------------------------------------------------1 
Factor V Leiden mutation i 
Prothrombin mutatior1 G2C2l0.-\. i 
Hyperhomocyste1."'1em.ia from mutations in I 
MTHFR ~rene- I 
I Deflcicncks of Proteins: C, S, or antithmrnbit! m 
!':,,!· Synthetic oestmg.e·n use 
Tobacco usc 
Other nwdica! risk fadors: immobilization, surgery l (c~pecially orthop~cdic ami pelvic). cancer, obesity, 
i severe i1hess, other thr"Ombouhilias ·----------~------------·-··-··-··-··-··-················..t··--------------~--~--~-----~--~---------
There arc a number of so-called "minor" adverse 
effccb thilt are wd1--knovm with OCF lJS<.:, su.ch as 
headaches, mood cnanges, nausea, and. bn:r,st 
tendemess. These effects are usually toietated, and do 
disappear with cessatlnn ofthe pill. 
Though often linked to OCPs, there is no dear 
evidence that weight g~tin is the directly caused hy 
OCP/COC use. Uterine breakthrough bleeding can be 
seen with OCPs and is a common cause for stopping 
the OCPs. Bn~akthrougb bleeding usually resolves 
··: 
., 
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\vith continued use ofthe same OCP. Occasionally a 
change to anothe~ brand is necessary. If the break 
through bleeding is signit1cant, the patient shots!d be 
evaluated fot other cm1set>. 
Adcikscents with \Veil--controlled diabetes 
mcHitus usually do weU with low dose OCPs; OCPs 
arc not continued if complications arise, such as 
hypertension, retinopathy, nephropathy , or 
r1europathy. Some clinicians recommend that OCPs 
be avoided in those with migraine hc~ad<:.ches having 
auras and in thosl) \Vitb. worsening headaches on the 
OCP. 
Some anticonvttlsanLs lead to reduced OCP 
efficacy. These include barbiturates, phenytoin; 
carbaxnazcpiEh', feibamate, t()piramate, and vigabatrirL 
A number of other medication:; can also interfere with 
OCP efficacy, such a.s rifarnpin, gri,.;cofulvin, 
ketoconazole, Hraconazole, and others. Antacids and 
OC?s should be separated by at least 3 hours. Those 
>vith c.cti vc: Liver disease should avoid OCPs. 
I'ra.nsderma1 hormonal contraception 
Ihe use of the patch to provide contraception has 
become a popular method for many adolescents and is 
based on decades-long research in using tra.n~dermal 
rnechanis:ri1s to deliver medication. Patients should be 
advised that the same adverst: effects as OCPs apply, 
with the possible addition of increased tm~ast 
syn1ptoms, and 1ocal dermatitis at tbc patch slte. The 
c:ontra1x~ptive patch is about the size of a matchbook 
and placed on th~ skin in various .sites: upper outer 
ann, buttocks, upper torso, and abdomen; it is not 
placed on the breasts or skin tbat is irritated or cut, 
The patch produces a daily release of 20 meg EE and 
150 meg of norclgestromin, a hormone that i~ the 
active metabolite of nnrgeslimate. The patch is 
typically start~d on the first menstrual day, replaced 
weekly for three weeks, and then no patch is placed. 
on week 4 alkr.ving menses to occur. A Quick Sta;-t, 
as discussed above, may also be used for initiution. 
A dil:Iere:nt site is chosen with each patch application. 
Pregnancy rates ate simUat to the OCPs, 0.7 ro 
1.24 per 100 \l.'oman--ycars with the patch versus 2.18 
for OC:Ps*. This rate is net affected by exposure to 
watet baths or saunas, strenuous exercise, or wa:~m, 
humid climates. increased r~sks for pregnancy include 
wearing a patGh over 7 days, patch detachment, and 
not placing a patch afLcr being off for 7 days. If the 
patch detaches, [t should be reattached lmmediatdy. If 
the patch cannot be reattached wtth its own adh~3i.ve, 
a new patch should he placed and the patient should 
place the next patch on schedule. Tfthe patch is off tor 
over 24 hours or the patient is more than 2 days late in 
changing it, a hack-up contraceptive method should 
be used for 7 days. Some concem has been raised that 
pregnancy risks rn<'-Y he increased in fcmaks over 90 
kg. COC efficacy is reduc~,;d in cbese females but is 
better than noted with use of barrier methods alor;e, 
This reduced. efficacy is due to increased basal 
rnetabolic rf;l.tCS, augmen-ted adipose tf~suc 
sequestration, a.nd increased hepatic metabolism of 
enzymes f<ll..lnd in obesit-y. 
N uvaRing vaginal ring 
Nuva.Ring is a flex[ ole, transparent, soft vaginal ring 
made cf an ethylene vinyl acetate copolyrn~r with two 
steroid reservoir cores providing a daily release of 15 
mg EE ami 120 meg of etonogcst(el (desogestteJ 
metabolite). It is placed in the vagin<:! by the 
adolescent for three weeks and ihen removed for one 
week. Quick Start is possible. If the ring is expelled, it 
;s sirnpty cleaned and placed back in the vagina; if the 
ring is removed fbr nver 3 hours, l1 back--up method of 
contraception is needed until the ring is back !n the 
vagina for 7 days. 
lt is an excellent meth:J<l of contraception for 
those who are comfortable with thdr bodies. 
Adolescents are ;jfkn reticent to use the ring due t<j 
the method of insc;tior, and removal. Insertion (~a:r: be 
simplil1cd by placing the NuvaRing in an empty 
· tampon applicator and using the applicator to insert 
the ring, The user ne~ds tn be: counseled that the ring 
does not prevent STDs. 
Advantages of the rhg indnde exi;ellent 
contraceptive efficacy, easily placed as well as 
removed, confidential method, continuous hormone 
release, and rapid return of ovulation after cessat!on 
crf the methi.Hi, Potential adverse e!Tects include 
vaginitis, vaginal qiscornfurt foreign body sensation, 
as \.Vel! as the common side effects of all COCs as 
mentioned above. 
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Contraception 411 
Progcstin~only pills (POP~} provide wntracepdon by 
cervical mucus thickening and endometrial atrophy; 
ovu1ation 1s rim reliably inhibited, leading to 
pregna.tK)i rates of 1-3 or rnore per 1 00,000. 
Prog{~.stin::; used in POPs include 0.35 rng of 
norethindrone (Mictonot@; Nor-Q,D®) and (1.075 mg 
of norgc;;.trd (Ovrette(R)), 
POPs are suggested by soln<~ dlnicians for 
sexualty active females with c. contraindication w 
estrogen (such as hype11ension or coronary heart 
disease). They are also used in females Vl•ho are 
breasth:eding. Typical adverse effects of POPs 
include amenorrhea and irregular uterine bleeding. 
PO?& ~hould not be used by females with eCtopic 
pregnancy history or taking certain medk:atlons, such 
as antkotnrulsants, rifanipin, and griseofi.1lvin. POPs 
are not typicaUy recormnended for adolcsc:cnts due to 
th~: above increased pregnancy risk and the need for 
an active piH (no placebos) to be taken at the same 
time daily making compliance diftkatlL for teens, 
Emergency contraceptives 
Table 12 lists some of the emergency contraceptives 
(ECs) that have been available (28). The Yuzpe 
regimen Uf>es a combination of Ef! (1 00 meg) and a 
progestin and results in significant. nausea due to the 
high dose of estmgen {use of antiemetic is 
recommended}, while Plan H contains kvonorgesLrel 
enly and thus produces less nausea and has been 
shown to be somewhat mor~ effective than the Yuzpe 
regimen. The n;pccted pregnancy rate from one 
unprotected coital episode is about 8%; this is reduced 
to less than 1% with some FCs if used within 24 
hours of unprotected sex, EC is most effective if used 
within the first 72 hours after unprotected sex t)r 
contraccpti£m failure, but may he taken up to 5 days 
after coitus. If the patient is pregnar1t while taking 
ECs, the fetus is nm harmed. ECs are over-the-
cowiter in many parts of the world. They shm1ld not 
be used as regular contraception, Reasons to nse ECs 
include having sex \Vithout protection, slippage or 
breaking of a. condom, missing 2 or more oral 
contraceptive pills in a row, barrier contraceptive 
dislodgement (such as a di~phra.gm or \x~rvical cap), 
intrauterine device (IUD) dislodgement, or being owr 
14 weeks from the la~'t Depo~ProveraCBJ injection. 
Medroxy-prcgcstcrone 
DMP/\,) is a commonly 
that inhibits ovulation. 
al;etate (Depo~Provera@; 
used injectable contraceptive 
th[ns the endometrium, and 
thickens the cervi<;al mucus. l.L is most commonly 
used m the intramuscular formulation, but a 
subcntat1ecus version has been developed which m:ay 
show promise for self administtation in the future . 
It is a reliable contraeeptive if taken on. a regular 
basis at a dose ofl50 mg CV(oty 12 weeks. A very low 
pregnancy tate js noted at O.J% .. It does not contain 
estrogen and thus, can be used for those ;.vith 
contraimlicatioas to using estrogen. Bone loss is noted 
ili, adolescents on this contraceptive ·· an average of 
3.1-5% after 2 y~ars of use. However, several studies 
have shown significant bone mineral density ;·ecovery 
after cessation of DMPA, thot;gh it is tinciear yet 
whether DMP A decreases peak bone density \vhen 
used during adolescents. Therefore, DMPA should be 
used with caurion in youth at risk for low bone 
density, such as those with chronic renal discr,sc, 
anorexia nervnsa, and those with limited mobility 
(29). Use of Depo-Provera often leads to irregular 
mcnstrualperiods and then, amenorrhea. 
··--·--·-·-·-·---·-·-·----·-·-· --:-----------------,---
;s OvTalt£: : 2 tablets hy mouth immediately followed by 2 tablets in 12 hours 
<~> LoiOvrs.l®, NorckUG@ or Levlen(ID : 4 tabs and 4 more in l2 hours 
l,. ._. TrlPhasilCK) or Tri-Lev1en® {yellow tnbs only): 4 tabs, and 4 mote in 12 h<)urs 
~ Ovrette®: 20 tab<> :rnd 20 nwre ln 12 houn 
~ Prevcn® Emergency Contraceotive Kit 
l ~ Plan B®: levo;orgestreL 0.751~~1> filllowed hv 0.75 rno in l2 hours -·--~----··--·------------·--~--···------·--------~---~---------~----··-··--·-- -~----------------···""'-- ·-- ··· ····-·····w .................. ____ .:_ ______ _ 
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Ac.oe 
Amenorrhea 
.Behavicrai. changes (depression, anxiety, ilTitabi.lity) 
Breast tenderness , 
Decreased bone densitv i J i 
Dizziness ! 
Fatigue . 
! Glucose inwlerance 1 
! Hair loss : 
' Irregular menstmal bleeding i 
Nausea J' 
.... ~Y.~~ght gain -~------······························'"····----------------·------·----- -----·-----------
·-.rab1e 13 provides a partial list of adverse effects. 
Bcnef21s of this contmccptivc include. re1iable 
contracqition, reduced dysmenorrhea, .less seizure 
a,{:tivity in some females with epilepsy, and lower 
premenstrual tension syndrorne. 
Other injectable contraceptives that are available 
Hre LunelleJJ) (United St:;:tes); Cydo-Provera, and 
Cyc.lofem (5 m.g e,st:radiol cypionate anct 2.5 tng 
medroxy -progesterone acetate fMPA /F:2C]); these 
corobinatio.n injcctablcs (containing estrogen and 
proges.teronc) ~re given intramuscularly every mont..lt 
(every 28-30 days) aml have v~ry high contrac.eptive 
efficacy . Si.nce it cnntains estrogen, dysfimcti onal 
uterine bleeding and amenon·hea arc not as common 
as noted with Depo-Frovera. Another injectable 
product is J\.ksi:gyna® (with 50 mg of norethindrone 
and 5 mg of estradiol valerate). 
'l'ht: ctonogestrel-releasing implant ((l.vailablc as 
Implanon® in the US £>ince 2006) is a subdermal 
implant consisting of one 40mm long, 2mill diameter 
.rod. This rod Js wade up of a core cqntaini.ng 68 mg 
of ctonoges't!~ei within a rod of ethylen¢ vinyl acetate 
copolymer covered in a mcrnhcrane nf the same 
matcri<J.l . 
Thi::1 implant is inse;ted sLibdennally, t);pica1ly in 
the region of the bicipital groove, using 1hc sterile 
preloaded inserter. I.mplanon provides 3 years of 
contraception by releasing a steady dose of progestin 
ca;;sing inhibition of ovulation and increasing cervical 
mucus viscosity. As a progestin-only mctl1od of 
contrac.cption, the implant does not have the side 
effects or contraindications associated with estrogen. 
containing methods . Unlike Medroxy-progesterone 
acetate, the implant does not c~mse decreased levels of 
estrogen and thus does not decrease bone density . 
The benefits include high efficacy, long-acting, 
non-estrogen contain1ng, -.ost effective, rcquin':s little 
e!Tort of th: part of the patient, rapid rewm to 
fertility, <:md the benefits of other progestin only 
me\hods. 
Adverse affects include irregtllar bleeding, 
headaches, acne, weight gain, pos$ibk rnond 
disturbance, and increased blood pressure. If irregular 
bleeding occurs, the patient shou!.d he evaluated for 
other causes. 
f.f no other cause is found and the bleeding is 
significant or disruptive for the patient, NSAlDS, 
combined oral contraceptives (varying regimens), or 
et.hin_yi estradiol have been shown to be effective to 
tl'eai brea.k throl<gh bleeding due lc the hnplant and 
pos.si,.~ly other progestin-only methods as welL 
The eflect of Implanon may be decreased ih those 
with liver disease and by medications that induce 
CYPJA, :mch as many antiepiteptics, r ifampin, and 
St Jr)hn 's wart. Ukc DMPA., many women eventually 
experience amenorrhea with the impiant. Barriers to 
use ~ncludc cost and the need for insertion and 
removal. 
The need f<:>r removal by a trained profe.ssional 
may also be -seen as a be.net1t in the adokscent 
population as this gives the prac1:!1wner an 
opportunity to couilSei the patie11t on family planning, 
safer sex practices, additional contraception options, 
and conduct appropriate screening prior to the 
adolescent discontinuing t.:.1is method, which may 
decrease unintended pregmncy. Overall, implantable 
contraception is an excellent option for teens. 
..··.· .· 
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Intrauterine device {llJ D) 
. A nu:m.ber of IUDs are available in the world: the 
three lypes avllilahlc in tJl(~ United States are 
Progestasert IUD®, the PamGatd® (Copper T380A) 
and the Mirena@ HID. ·rable 14 lists the 
contraceptive mechanisms of IUDs. Pmgest(l:>ert 
IUD@ is replaced annually and has an: expulsion rate 
of 2.?%, \Vhile ParaGard@ is replaced every 8 to IO 
years and has an expulsion rate of 5%. 1n Lhe United 
States, concern has been raised abottt a possible link 
betM.'ecn its nsc and peJvic inflammatory disease in 
female:;; due to often criticized research d.Htlng to the 
1980s. Though controversial, it has 1 im ited the use of 
IlJDs in adolescents in the U.S; it is used by 12%, of 
contraceptlve.using women throughout the world. 
Data on the currently avai!ablc IlJDs show no 
increase [n risk of PlD unless the patient has an 
infection -,vith Chlatnydia o:- gonorrhea at th~ lime of 
p1acemenL Therefore, patients should be screened for 
STis prior w fUD placement 
--·----~------·------,-----·-·------·-·-........................... .. 
1. Prevents fertilization 
2. interferes \Vithovum dcvelopme11t 
3. Interferes wtth sperm movement an4 ability to 
penetrate ovum 
4. T:nh!bits ;;penn survival 
5. Helps prevent egg release 
6. Thti:kcm; cervical. !YHlCU.S. 
Mirena lUD (.Lcvonorgcstrel-containing IUD; 
LNG--IUD) is a second .. generation of steroid-releasing 
TUD. It releases 20 meg of levonorgcstrei per 24 
hours over the f!rst 5 years of use, decreasing to 10 
meg per day after 5 years. 1t is. a popular ru D used by 
over 2 million women in the world. lt has a failure 
rate of 0.2% in the first year and 0.7% at 5 years. It 
exerts a local effect on the endom.et:rium as well as the 
cervical mucus; ~.wul!ltion may continue and 
endometrial thin.r:ing can lead to aJneDorrhe~t. Table 
15 lists potential adverse ei'F::cts of Minma HJD, the 
most common of which is irregular bleeding. It has 
been used. to reduced menstrual bleeding in. females 
with dysfunctional uterine bleeding, because it can 
reduced menstrual blood loss hy 90'Yo. 
Contraindications to Jvf1rcna IUD use include 
distorted uterine cavity, bistory of St~b acute bacterial 
endocarditis, prosthetic heart V<J.1ves, and active pelvic 
inf1atnmatory disease . 
Tab!e 15. Mtrcna.lUD Side Effects 
.................... ----------------. 
Common 
Initial increased menstrnal bleeding. 
Abdominal pain 
lJncomn;on 
Acne/other skin nrobJems 
Back pain _, 
Breast tenderness 
Headache 
Nausea 
.l\-1ood changes 
Rare 
Hyperscnsiti vi ty reaction 
IUD become~; embedded in myometrium 
Perforation of uterus or cerVix 
ParaGard® (Copper T380A) is a copper T lUD 
which prevents pH~gnancy by the interference of 
sperm motility by the copper ions. PamGard® is 
highly effective INith a first year failure rate of OJ~% 
with typical usage and a high rate of continuation 
among adolescents. The primary b{mefit to 
ParaGard® is that it is non-hormonal a:"ld can 
therefore be used as reliable contraception in those 
-,vith contraindications to hormone use, history of side 
effects with hormonal contraception or those patknts 
\Vishing to avoid hormone usage for other reasons. 
Adverse effects are primarily increased dysmenorrhea 
and menstr:..:al bleeding, abdominal pain:, ex.pu.!sinn 
and rarely perforation. Contraindications are similar 
to t.:.1ose for Mirena. in general, lUDs are a safe, 
effective, long-term method of birth corrtrol that can 
be used in nulliparous adolescents. \Vhik not 
recommended for teens at high risk for STls, IUDs 
have not been found to increa~c risk of PID, nor have 
they been found to affect future fertility. 
Barrier :methods 
Diaphragm and vaginalspermicides 
Table 16 lists banier contraceptiv(~S. Tbes;:. methods 
are only recommended for highly motivated sexually 
c.ctivc individuals. Clinicians can lca.m to fit 
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diaphragms, help determine the proper size and teac;h 
the youth successful use of thio: methoi.L The 
diaphragm is used >vvith vaginal cream or foam and is 
often used with the (:ondom. Vaghal contraceptives 
or spertnicides include foams, jellies, crearns, 
suppositories, and a tCntmceptive film. 
Contraindications to diaphragm use are listed in Table 
17 and advantages of vaginal contraceptives are listed 
in Table l 8. Side effects inc!ude vagind odor and in 
mre cases, allergic reactions. Females w·ho have 
diabetes mellitus and use a diaphragm have increased 
risks for urinary tract infections. 1n rare cases, tuxic 
shock syndrome may occur and the diaphragm is 
conrraindicilt~d in a female having a history of toxic 
shock syndrome. 
Table 16. Vaginal B!lrder Cm&tracepti.ves 
....-----"'"''"'"''""'"'""'"'"'"'""'"'""'" ------·-··············, 
Diaphragm 
Cervical cap (Prentiht')) 
Vaginal contraceptive sponge 
Vaginal spennicicks 
Femal<:·condoxn OlealltyCRJ) 
! 
! 
! 
l 
! 
! 
! 
! 
! 
' t Male condom 
.................. :=::...:.=:._ ____ , ................................. __ ___; 
Table 17. Contnlindications h> Ust; ofth~ Di~puragm 
~-~-~ ................................ .. 
AllcrJ;<,Y to rubber or spcrmicides 
A.nteversion (severe; f<.nw~t.rd tilting of uterus) 
Complete uterine prolapse 
Perineal tears 
Retroversion (severe; backward. tilting of uterus) 
Short anterior vaginal waH 
Vesicovaginal (or rectovaginaJ) fir.tulas i 
Toxic Sho_~~.-~:Y.~!-~~:~~~!e_-_______ ................. .! 
Allows the mnr to shar(~ contraceptive i 
responsibility when used 1-vith a condom i 
Can reduce: dyspareunia if present (vc.gimil j 
lubricat~t) i 
Cost is minin1at ! 
Prescription is not needed 
Provides effective contraception, espeddly if 
used in conjunction with COi1dom or diaphragm 
Side effe.cts are f~w1 
Useful for young women witb only occasioha1 
coitus 
--·····--··---··--···········----------
C"'!ervical cap 
The PrenH® cavity-rim cervil~al cap is a smaH, latex 
cap ('Nith spennicid~ p1aced insi.dc) that is hc.lf the 
size of a diaphmgm and. fits around the cervix vla 
suction. FouT cervical sizes are ava~labk and about 
one-fou.rth of females cannot be fitted with a cervical 
cap. The clinician should obtain cervical cyw)ogy 
betore and at the time of cervical cap fitting because 
cervical dysplasia has been reported in cap users; 
additional cervical cytology i1> also recommended 
three n:wnths after the fitting, Contraindk:atinns to cap 
u;;~~ include cervical laceratitm, cervical scarring, and 
a history oftoxk shock syndrome. 
Vaginal contraceptive sponge 
The sponge is made of polyurethane with 1<. concave 
:.<hapc; it is a disposable method available without 
prescription, inserted in the vagina up to 2 days before 
sex and lefi in place 6 to 24 homs after cohus. 
Adverse efTects inchide vulvar rash, vaginal odor, 
pruritus, candidiasis, and increased risk for nrinary 
tn~ct infection as weLl a:; toxic shock syndrome. Its 
contraceptive eff'.cacy is similar to other barrier 
contracepti\ics. 
Female condom 
The female condom is a polyurethane bag or sht~ath 
that does not require a pn:.~scription. H is placed in the 
vagina prior to coitus; it is not used with a mate 
condom. Some STD protection is provided by the 
fen1ak condom and its ov{irall contracept[ve efficacy 
is similar to that of other harriet con\:raceptives·---· 
acceptable, but not as good as oral contraceptives. 
lviale condom 
!Vlale condoms ;1re recommended to reduce the risk 
for STDs a;s well as pregnancy. Their contraceptive 
effil~acy is similar to (?ther b<1rrier methods. They must 
be Llst:d com~ctl:y vvith each act of coitus or their 
efficacy becomes considerably reduced. 
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Contraception 
Latex condoms are associated wi:tll inc:n~ased 
breakage rates when exposed to high temperatures 
and/or ultraviolet ligr:t; they are also \veakened by 
exposure to oil-based lubricants. Latex. allergy is 
noted in 7% of the general population and. the 
polyurethane condom can then be used. ln genera\ 
!Ttale condom usage should be encoumged. in the 
adolescent population primarily for sexually 
transmitted infection (STI) prevention. Ho\vcver, 
barrier methods are typkal1.y not recommended as the 
sole method of birth comro1 in adolescents. 
Conclusion 
Contraception is an important concep.t for sexlca..Uy 
active youth who wish to prevent mnvanted, 
un.pianned pregnancy. This papet has fi~Vlewed 
effer;tive methods of contraption that ax~ available. 
Clinicians caring tor adok;Scents should ask abcmt th.e 
sexual behavior of the~e youth and provide advice on 
contra<:eption, beginning with abstinence. 
Sexual responsibility involves prevention of 
unwanted prcgtw.ncy, prematu.re childbearing, and 
ST1s. A surmnary of contraceptive options for 
sex;;aily active adolescent females having chronic 
illness is provided in Table 19. 
Table 19. Chronic Disorders autl Contraception (Greyd:.nms, 2010; ZOHI; WHO, 2004; 2008; CDC, MMWR, 2010.) 
!,',,,',,,',,,' ,_:·:",n()ti[p
1
_-P·.h.i_o,js- . DMI';\ or the Mirena fUD/1US See increased risks for thombosis tn 
, " the~e patknts and thus, avoid COC.s. 
AntibDdy Avoid COCs in these p<11i::nts with 
(aPf) n:wdcratc or high titers of 
Syndrome anhphospholipirl antibodies (i.e., at 0r 
over 40 GPL or MPL Lmil:s). 
Risk of thrombosis is 
cspcc! ally incre.ascd if 
oth{;r t;sk factvrs tor 
thmmbosis are present 
>·~·:------"'""!"-:~-····----·--·--·-·-------·--·-.--·······-·--............... ~·-······----·-----·-·-·----·--·--·--·--·'--······· .. ·········· ...... i Cancer Potentially All Methods; see- vm·ious COCs a.rc contraindicated i!l 1hose with 
-----~--------~--~----------------------~----: 
COCs m3y reduce risb l 
: 
' 1 
! 
! 
cautions. ~·or example: breast cancer. Progestin and estrogen for.ova:rian and : 
endometrial carcinoma. : : 
Pr~:E,"'I<mcy wurs~::n~ breast f 
I 
Avoid DlV!PA if taking receptors arc noted in ovz.rian c;.;ncer 
cbcmoth,~rapy dc;<; to increased risks tissue: thus, COCs ;;.rc not prescribed to 
for mf(;ction trom roec;iropt~nia or an patient> with ovarian cancer. A ..void ih(; c~nccr~ cndorn.etr.!ai 
inJcCtion-i:Jduced h~::mawma due to mini-pin with a posith.-e hi~tmy for ~ancer, ovarian cancer. 
th.romhoc)topcnia (t CP). ecwplc pregnancy or if taking meds. malignant gestational 
Cbemcthcrapy-ind;.Jccd bone kss \Vlth drug interactions (i.e., certain trophob!asli1; disease, 
may be m~reased by DMPA. Avoid a...'l.ticonvulsant:;. g~·ise0fulvin, rifampin). malignan1 Ever tt~rnors 
TUDs ior those wi1h ne1~tropenia m (lwp<s.toma) and 
TCP. C:ru;:ion >Vith ~:qntmcep1iye l;epatocetlular Ever 
! hnplants for those \vilh TCP and carcinoma (CDC, 2010). ! 
! ~---c~--:---:-----i~1rr,..,..~":g::-u..,..la_;_· n_,J7e_n_~i:-;-'·u_a'-lc:b::-l_e_c.:..d_in'-"g.:;:.··----+-:=:----=:-:-:--:--:--~---:--:--:---::--+-:----::---. ·--·-·-·--·--·-·-·-·-_j Cun.gf.nilal DMPA and min~·pi1l l).re Th(lSe on COCs have insJeast:C! tisk fo~ Fe:nalcs with v~.lvda.r 
.!-kart rt:etwmwndcd for thos{! with CHD u· thmmbophlcbitis, vascular tf::rnmhn~es !!<::art disease <md other 
Disease stable. Mirsna EJD/HJS h nsua!ly (attcrial or \'enous), and pulmonary GHD may be at 
(CHD) OK. Observe for potential adverse embolism. Void COCs (im.~luding patch) cndoc-a.rdit].s risk clnt[ng 
reaction~ during nJD pla;;ermmt, vvi\h a positive history for these IUD placement and 0ne 
such as syncope., bradyt,a:rdi<~. lmd c0nditinns. See the >ext. .rnonth after the p laccnwnt 
seilures .. Avoid JUD if patient is on 
~! rrtit.nagJ.J laHoa due to incre.as~~1 ris~. 
for bleeding with IUD placement. 
Avoid COCs if there ls ir.creg.sed r:sk 
for thrombo·Emho1ism or 
cndccardnis~-depcnding on the type of 
CI·ID. COC:; (im:1uding Llu; patch} arc 
avoid\:d in \.hose with CHD with cmdiac 
shunts! congestive ~1earf diseas~: !ow 
outputcurdiac disorders, il.·'ld r;nmnary 
heart di,;ease. Avoid.COCs (includLng 
patch) in. those vdth CI-IJ) 3.:ad 
l'regna.'l.ey 1s a,;sociatcd 
with incrcas<:d adV{;fSC 
health effects in ischemi.c 
.her>.Jt d.isease, complicated 
va lvnh;- heart disease, 
pedpartum cardiomyo-
pathy, stroke (CDC, 
20 lO). 
··--·--·--·--·--·-·-·-·-········---·--··---·--·--·--··---·--··-'-··P.:!;~:~.?.~:~:Y..!'-lE.er\c~si_o_n_, _______ ......._ __________ ...,~ 
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: 
~ j 
All methods art acteptahk if 
the metabQHc status is stable: 
COCs, DMT'A. mini-pill, lUDs, 
mini-pills. 
T!lble 19. (Cmttinued) 
Coi1ccrns 
COC5 5h0uM be uvuided h1 any 
adolescent female: \ViLh diabcti;; 
compbcations (pedpherul V<lS<:ular 
disca:oc, ncph:ropatily, and retinopathy), 
va:-!culr:.r s~quc]a.c (i _.e., -venrlus 
thwmbosiS), or hypencnsion. DJ'vlP A i~ 
S<lkev~.n with the presence ofdiabct(::; 
compl;catioos. IUDs IrElY in.dm;e dt.ronic 
or resistant Canditfq afbi.cans v.a.gi.niitis in 
some. 
COCs do not worsen the 
tnetaho;ic status. Nc\v>':r OC 
progc~tin~ (norgesti,'"Datc, 
gcstodcne, and dt:sogestrel) 
may cause lcs;; carbohydmLe 
metabolism dkcts than the 
older progcslins. 
Pregnancy is as~udat•:ii with 
increased adverse h~·i:llth 
effects in lnsu1irHiep~;ndu:nl 
l diabetes meifit!ls with i--·i::pii~ps):·-----·-tnMi>;\;-'rUi).(Mi;;;~·-;,~a····--------tc:;-,;iiO-i~-v.iti1-c55t:~·~;~;-~;-~;~r-e-~~~;·t;;··-··---- -~~~~~~~i~1~~ifi~¥.~~:,l~,olo; . 
. copper); Barrier wntraception :,i'',,,',,, interfcn~ncc with some an.ti::pileptic inen:.:JS('.d ri:>k tor pn:gnmu;y 
dmgs with i.."lercascd pregnancy risks: and pokntial teratogenicity of 
Catbamazepim: (Tegn•:ol) anticpikpuc mcdkations. 
Phenobarhitai Pregnar;;;y lS assc1ciated with 
, Phenytoin (Ditantin} increased adverse hc~.lth 
i Primidonc (Mysolir.e) . effects in epilepsy (CDC, 
i Topiramate (mild inducer)(Tapamax) ! 20 i 0), 
.................................... _. ............................. _. ... _ .................... t··----·---·,··:··::----:~----.-···:·--·---· . . . . . ~--·--·--r .. , ............ , .......... ---::,----........; 
Hyper- All methods il.rt rccommcnned AvoHl CO~-~ ;f :ow de.tiSli.y hpopwtems i Res;;;arch nok~ t..'lat estrogen 
1ipidemia for stable hyperlipidemia .. Use (LDL) level is over 160 mg!dl, l can tower high density 
Jow-·d\)SC COCs. triglycerid-;;s arc over 250 mg/dl, nr in j lipoprotein levels, r;tisc LDL 
sit.nat1ons with the existence ofm~c!tipk ! levels,. and increase 
r-i$k f;lCtOfS' for C0(0tl(H)1 artery d_igem)e. 
(CAD): diabetes meUitus, hypertension, 
obesity, smoking and positive faa1i!y 
trig !ycerid~ levels. 
history for premature CAD. 
r-.-:-c--~-·-·- ........ ~--;---::------:--c:--:----+--:----:--'-----'..O-'---'--'--:--c-'--'--~.,......,,..---1--:-:--:-:-:c-----:--:---,.,.. }·lypef\en- Al] mctbds are used ;JjJle-: Avoid ~strogen .. cQatnining m~lhods for CO(:s re~u!l in a small 
sion ;;(~ndition is stable. unstable hypertension (such;~ bbod incr<:a~e in h]o,,d pn:s~u..:.·<.:~· 
prct>~ures over 160/ W{l mm !!.g), highc:rincr.::ase in ~mecdot:::.l 
?·regnancy is associ;!tt:d vl'ith increased si(uations. 
adverse hea.!tll ef1~n~ in um:cmrolled 
hypcrknsion (CDC, 2010). 
.. ...................... ~~-~----·----·----+---------................ --:----:--:---........; 
COCs may reduce bowel symptoms in i DMPA may reduce break.-· --+-.,-:---·-----.................................. . Inflamma- AH methods are usllillly 
tory acceptable, A. void DMPA on a 3.ctive en litis; COCs dficncy may b0 
lowered d;Je tn inc-reased br0ak-fr ..mugh 
bkedir.g and reduced OC c~bsorp!iD!L Use 
tt;e patd1 if ga~trc;inte!;!.ir!~l absorption 
way bt: ap!oblcrn. Mirena !l_JD/!US 
j through ·ble~diflg and 
Bowel prolonged basis in those on : : serondm:y "n..:mia; may be 
hest tor combi!1a(ion of IBD Diq::ase corticostemids chle to bone lnss ! 
(IBD) t;:cK~exbation. I and coag;;lation disorders. 
nppe<1rs to l:J<:, dketivc 11.nd safe. 
~--:-:--·-----··-- ............ ~-;----;--,------+--
lntcllcctual Sec schizophrenia 
Disability 
-~--.. 1 .. l)Mc::P-c-1-c-\-a-t-,(..,.i...,!""t""; =D-s-,-,r-e--s-a..,.fe-,,-, 1:-. t'h-t--1\,--v-o-c-i-:--d COl's in t.hose with-;z~-v~~t'i_v_e_r--+-,-! n-(-,: 1:-d:-<:-.t-;c--~::-o"""r ... h .. e-. pa-ti~·;;·ic·-- ·--·--·· 
! activ<! liver disease. Barr(e;· d[~ase (indudir;g hep2,t[tis anrJ adenoma is 3.4/!00,000 pHi I contmce.ption i:; also fin;; cirrhosis). COCs are 0[( when the Ever users. Pregnancy is us::>ol~iatcd 
! (ex<xpl for-the increased function te~ts retllm to normal. linknown w·itii incrca~ed adverse heslth 
Liver 
Disease 
! pregn<Jncy risks inhcrcm ir; th;s \be effect of obt:sll)'·induccd NASH df<c:cts ;n severe (deC".ompens-
! method). (non-alcohn!ic steatoht:paiitis) em CCC ated) cinho:;i~ (CDC, 2010) . 
..-~·-·----·----·--·---------~-------------··---·--··---------·--- .. :?!!}E~~I: ............... ------------1----------------i 
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r, ··· ········- ~ -~~ ·-· ·······--!. ·R~··::;:_·o-·rr.·-~r~. ·. ··n~(·~d "".t .".l"· ·t,",ol~ .-• __ ....... Tr.-~~- :.-n·;~;:~.·l·~.::·····-·n·······-·· ········· · · --~---··n-.· -·· ··· -··-··-··-··-·· -·--··· · ... -·--·· ... ·---f-.....,,......-.,.- -4-:::-- ~-~----"-':---:.-_~.:: ...... : ~::.... _ _ ~ ~ ..................... L~-~~~!.~!~:~::~.~.?.~_:_1:1~nts_. __ · ·---.. ·-·-...] 
Mlgr:;.ine i Depo-meciroxy- i Females witb cnmpl!c;1ted migmim: i l.J~e COCs with caui!on l.n those ! 
H eadache:; i progc:;;rror,e act: tate i hcad~chcs {Le, witl; neu:oicgical !.· vlith mlgrainer. ~wd stup if auras i. 
! i 
1 (DMPA), the mini-pili i symptom s) have heightened r isk tar ! develop andiG;- ihc headatbes 
I (progc~t::ror:c-0ni.y pU!), ! q:n:b<<J.l i~K:hemia and ccrcbmva,;sculat: j he~:om~~ worse. 
l tmd the Mi:rcna rm) rn I accidents (CVA5) ifpiaced on combined l 
i ndditton to barrier ! on;! wntra.cept!ves bec.aus~~ of estrogen .1 i 1 
. ! contraceptive~. 1 d tects I ["ob'e;i;;; ........... TL~~;~;~o•gcstrd mu arJc! 'TcocS.-;~:;-·g;~~;ct·;~~.TI~iien;_e_n_t_c..,·t-lP_i_c_~-,-~"".<.'-.r-. -i:~c""'o~c:~-- -<~-:r:-::fi:-c-·!1-,(.-.y-. .,..is_· _rL-·d·;;;<;~r·;r;·(~J;;;-;;;·-
! ! rnini-pills .may be .tbe hest i obese y .mth needing contraception a;: i tcmal~s but is bette~· thar, use of i i option Jig lh(;; morbidly i w ell as pc·lv(vst.i(' ovarv svn·h·r>mr· 1 barder methods ~! kate., The 
1:, 'i o'--~e a"<'.!.~ s~.:-..._n :~- . CO'"l~S !lr i,. . . .. .... - . ;,. •d.; : .~ ... ... _ "":""·.'-·- ...... , i: d d t""~ . I "r 
'""' '-' ·• - ,._ .. ~ _ . !llt,.JU5m, an acne vu;gans. i re' ucc· e !It;-(lcy :s (.ne <0 
i I i .. I t 1 in.tra.vagina~ ring 1rre ! DMP/\ may induce weight g<lin r:nd this i increased hasal mcta:ilclic rates, 1 i rcc.om;r:cnd~d unless l should be closc.ly monitored. ! a~1gmentcd adipose t issue 
an~c (as thrombo- ! hepatic metabolism of e:nzymcs. 
. . : 
i,:. ~ t~slrog<;u•;;ontraindicatlons i!. l sequestration, and in~;rcascd 
~ C[n bolisrn) other~) . t : ~ .. ·f;~~lmona.ryjAn mcthi;ct:~-;;:~~-u-~;;;~p:t~;;;~-~ .. 't (OCs arc safe and eft'ect ive ............. i-:c·aii .. tise .. ;\iEi-;;t·h;d~·:fi~·u~o-.-s-e-~-,·-lt-:-h-. -; 
~ Dise~c I in paiients with cy;tic ! in thu~t: with CP. l:>n.mclllai mucus l~ not i ~thma. IIpulmonary tubcrcubsis 
! fibrosis (CF} with np other ! thkken~d to a major ::;xtent (as with ! is p resent, rifilmpia can dect-..:asc 
: I ! 
cantraindl.ca}lons for 1 cervicatmucu.s) to interfere with COC efficacy. 
contraceptives. I contraception. I'ulmonacy embolisn r (PE) 
1
,1
':
! is a rare cvr.nt .... :?,void COCs if other high 
ri ~k fact~..'TS {OI PE arc present in cr 
rernates. 
Re;-u!"············"· ""i'f'tiic"tcnai"di~~~as~----·---lc-:cc:-:::o(:s liTe s~fC fo7'ESRi5'iTre~1~1T5tai~"'is'-;--;c:-:o=c:-:s-l_n_a_y"""ii_n_p_!~.()-V_C_l_n_c_n_o~-.r-:h-·a-g7ia-i 
Disease 
Rhew:nut-
. o id arthritis 
{RA) 
Sickk Ccli 
(indt1ding end sta~c renal 
rlisea<;e-.. ESRfl) is stable ·--
OK to w;e. COCs, DM PA, 
Mi~~cna ItJDf[(;$., llnd 
barrier con traception. 
cocs, De;;-:};;:o~era, 
Barriers 
noi .irnpuim l (~table) "Yith no 
hypertension, c~rdio·va'icu!ar di~>eas~:- and 
thromhoembo(ism. Estrngcp i~ 
contmindicatcd in those with hSRD wllh 
signilkant hypertension or if bed~ridd~r;. 
rtl some wilh ESI{D. 
I 
Avoid DMPA )Cboile ·klss is of concern. 
Avoid the 1U D with iJJ.cr~a~ed rb k of 
cndOnlttriti-s anri v~~ors·e~tin,g: ane:::~i!.~· ............ ) ...................... ------·--·--··-··-·--.--------11 
Potentl<tl concern. wllh IUDs du'-" to j Avoid COCs is L'le.-e is i:wn~;;scd i 
poten1iai infection. · risk fo r va>culitis, (}Qwrosd~ro· i 
Females with severe IV', ·may have li sis, or ischemia See pos~. ihle drug i 
diffiL'ulty inserting a vaginal r ing, i.·Hentc{i(l!lS between COCs anti i 
dia_phT~gm, cervit:itl cap, or ether barrie: RA tlnJgs, s ltch as warl~rin , i 
' contraceptives. cortiCostCr!).lds cyClospor.ine~ and ! 
i 
·-..... -... ...... -...... -..................................... _·-:---:---:---+-s-:-''..,.H...,r,..l e-:-:-a_n_ti,..c_o_,._,'~-~!:0.~:~::: ..................... ) 
COC:s .. IkJio .. J'mvera, Pregnancy in,;rca$eS risk for both mother Siddi'ng is a different process i 
I i i Dison.k:rs Baui•~rs and fetus. COCs do Ml increase risk dm: t..1.ml thrombosis :md thus, COCs i I (S:CD) 10 sid::.ling; Depo-Provcra may reduce do not increasC'l'isk Ji.)r l 
! ~ickling cr!se~. Pregnancy is as~ociated thon:-.bosis. l 
·t l, 
' with increased actvem: health e!J:bGL'> in 
t : 
t .s!·ckle celt disease (CDC!' 20 1 0) : ~ ... ... ... .................... .f. ........ ~·· · ·· ~·-~·-~· 
f Sl.E ! COCs nwy be the bc~t Avoid COCs in the preser:ce·;·[" .......... _ 
i (Systemi c i •~hoicc . vasculit is, nephr!l:i$, o r APLS. Avvid the l Lupus I prcg<~Kterone dmspirenone ifrerJal failure 
D.~~ -~JA n~ ay W'Orsen bo.rte t:oss 
already present ill SLf: patient !~ . 
Avoid the fUD due to the lowered i Erythem- i llot\:d since hypcrkalemi;;. c;m devel!.lp. irrHUUl'C ,.;.a ius c-f sr E patient< . 
i atvsus) ! Pregnancy is associated with ir;creased. . • ~ - . . • ~- . ... l 
: ... ______ ! ..... ----~ .. -........ -............. -,-:..~;_·~--~~· ...:,;:...s~~··_h_e_al_t_h_e_:ff_.c_·c_u_s_in_s_L_E_-' _(_c_D_(_:_, --...J..--- - ------.. -..... --.. ···~·_j 
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1'ab1e 19. (ConJ.inued) 
~-JI:,f;"sce!l.. HIV. DMPA 'Nork;; HJV: I'otcntid dwg !nteracticm between l!IV: use condoms as -;_ve!l to protect 
aneons v,-di. Altcrnat1ve: HJD. COC::; and c.:rtain ~.nti-I-IIV drugs; ~orne partner from BIV trilllsmission. 
cause dccrr:a.se in estrogen ((lopinaviri Pregnilllcy is assoc]ated witb 
ritanawr and nevir-apine) and some owsc incn:used adverse health effecls !n 
nn increase in estrogen (ala.:anavinmd H.!V/AlDs {CDC, 2.0HJ). 
'--------·-- ------------------·-·~-----'---"-f!}_i;_v_ir_::!El: ............................ ~-------'---~--------------------------------------··~----' 
Acknowledgments 
This paper is an adapted version of a chapter in the 
book "Adulcsccnt medicine: Pharmacotherapeutics in 
general, mental and sexual health" edited by Donald E 
Greydanq.~. Dilip R Patel, Cynthia Feucht, Hatim A 
Omar, Joav \1cnick at:d published with pem1ission 
by 'A1altcr de Gmyter. Berlin and New York. 
Internet Sites 
American College of Obstetrics and 
(Jynecology: http://www,acog.org 
Alan Guttmacher Institute, Nev>' York: 
http://www. agi -us a. org/index.htm1 
Association of Reproductive Hea.lth 
Specialists: http:i/www .arhp.org 
Cochrane Library: http://hiru .mcmaster.ca/ 
ccchrane/cochrane/cdsr .h tm 
Joumai of the American Medical 
Contmcept!on 
Information Center: http://w;vw.ama-
assn.org/special/conLra.hnnl 
Europ~.:an Jo:Jrr:ai of Contraception and 
Reproductive Health: 
http://www.tandf.eo .uk/joutnals 
Family Health Institute: hitp;//wwvv.fr,Lorg 
Center for Dise;tse Control, Atlanta, Georgia, 
US/\: http://v.'ww.hcalth.gov/healthypcople/ 
W odd Fl.ealth Organization Medical 
El iglbility Criteria: 
fll 
[2] 
[6] 
[7] 
http://www. who. int/reproductivchca1 th/publi 
c.ations/RTlR 00 2 
medical el igibility __ $econd edition/indcx.ht 
~ E:m.ergency Contraceptives Info: 
http:/h,,:ww.not-2-late.org 
Greydanus DE, Patd D Contraception in the 
adolescent: Preparation tbr the 1990'5. Med Clh1 North 
Am I 990;74(5): .!205--14. 
Grey•i&nu~;DE, }'atti DR. Rimsza ME- Cootrac!;)ption in 
the ad_olescent: An update, Pediatrics 20{)1: l 07(3 ):5fl2-
73. 
Greydanus DE, Rimsza ME, Newhouse PA. /l.doksccnt 
Stxtmli:.y and Jisabilit"j'. Adolesc Med Clin 2002;!3: 
223-47. 
Greyda.nus IJ E Mai:ytsina L 
Contmccptlon tor coUcgc students. P(~diatr Clin North 
Am 2005;52. 
!3.5-61. 
Greyda.1ws DE-, Bhave SY Teen contraception. b: 
Bhave SY, N;Jir MKC, Parthasarathy A, Menon PSN, 
C"rcydanus DE, eds. Bhave's Textbook :If a.dole~ce:1t 
medicine. New Delhi, India: Jaypee fhvtbcrs Mcdi.ca! 
Publish(:rs, ?..006: 173--8 .. 
Crcydarms DE, Hatim Hi\. Sexuality ISsues and 
gynecologic care of adolescent& with devdc.pmmta.l 
dis<\bil:ties. Pcdiatr CHn North Am 2@8;55(6}:1315-
35.Greydanns DE, Omar HA, Tsitsika AK Cnncepts of 
contraception for adolescents wilh obesity· Pathways of 
judicial moderation. Int J Child Heahh Hum Dcv 
2008; l( 4}:4.!1--9. 
Greydanus DE, Omat HA, Tsitsika AK. 08\~sit.y Hnd 
ct>ntraception. In: Omat HA, Grcydanus D!_:., Pat.d DR, 
Merrick J, cds;_ Obesity and adolescence: A public 
health concert. New York.: Nont Science, 2009:73-84-. 
:" ":}: 
:" ":}: 
"": }: 
.;:-: 
. ·:: : 
. ;::: 
-;· 
-;· 
. -;· 
. -;· 
:::: 
-;· 
< 
.. ·:· 
-;-
··.:::: 
·-:: .. 
[8) 
!9i 
f 121 
[1.3] 
[14'1 
!15] 
116] 
Ll7J 
[18] 
[19] 
{20] 
This artide was supplied to you by Clllldren's Mercy Hospitals & Clinics' Healtl1 Sciences Library. 
NOTICE: The US. copyright law (Title 117 U.S. Code) governs reprodllcUon of copynghted material. The person 
receiving this article is liable for any infringement of thiS law. 
Contraceptio~! 41.9 
Greydanus DB, Mnl:y!sLi:ait LA. C<mlmceptiou (t! 
adolescent females wirl1 chrenic illness: A clinicai 
n:vie·.v. b1 .r Child Adolcsc Health 20]0;3{2):222-31. 
Gre)'dmms DE, Omar HA, Matytstna L, Tsltsika AK. 
Contniception. b'i: Omar HA, Grcydanus DE, Tsitsih 
AK, Pa;:el !)R, Merrick J, eds. Pcd[atric and ad0h.:scem 
sexuality and gyn~cology: Princ.iples ror the primary 
care clinician. New York: Nova Science, 2.010:413-70. 
Heroux K. Contraceptive choice.~ for medica:tly ill 
adolesce11ts. Sem Rt:pmd l\·kd 2003;2l:3R9··98. 
Kaunitz. AM. Clin ical rrH:mag(:mcnt guidcl·incs· fin 
ohs:.etricianScg)'ltC4~oklgi~t,. Use of hmnonal 
contraception in wom1!n with \:o-exbting mcdjcal 
conditions. Obstct Gyr.ecoi 2U06;l07{61 ): l4S3-72. 
Leeman L. Md.icai hanicrs to effective contracep!i.on. 
Obstet Uyneco! Ciin Norti1 Am 2007;34:19·29. 
Quint EH, Breech L, Brown CM, Kiv~!< S. 
Contracx:ption in tceris withtnedical pn3blerns. J Pe<liatr 
Adoks<'. G;mecol 20:05; liU93-5. 
Spt::n\:er A, BonnemaR, Mc\lamara M .. ! leipit<g women 
choo~c appropriate hormonat contraception: Update on 
d.sk, hel1et!.:s, artti )ndi(:<llions.Am J M~d 2009 ;122: 
497-506 . 
Teal S.B, G1nos~r DM. Con1racept!m1 (or wor.nen with 
'~hronic medic:tl condJt!ons. Ob~tet Gyneco! Cli.n North 
Am 2007;3'U 13-26, 
Gitte~ E.B . Strickland JL. Contraceptive cnoi<;es for 
chronicaliy ill a4ole:>cenK Adolesc Med 2005;16:().1:5•· 
-H. 
Fonseca li, (ireydam;.s DE. Sexuality in the child, teen, 
and young adult: Conccp;s tor the clinician. Prim Care 
C!in Offic. Pract 2007; 34.275-92. 
World Hcultl1 Organi:z:<:iton, M.edkal eligibility C riteria 
fbt conl.raceplivc u~e, y! cd. Ger,eva: WHO, 2004 
World Heahh Qrganizati<m, Medical cligib1lity Critcri<l 
!'c:r contraceplivc usc. Geneva: WHO, 2008. 
World Hcuith Organization. Selcctiv;< 
rr:.\:Gn-till(\ndations far cnntn::ceptive us~, 
Geney!!: WUO, 20G4 . 
practice 
2nd t~d. 
(21 J Cerlte~s tor Diseils~ Control. and Prev~ntio.rt. L'S medi{'.al 
cligihility ctiteria for contraceptive use, 2010. MMWR 
20 W;59(RR-4): l-IN. 
122] Bigg~ WS. The family physic inr.'~ chailcngc: Gttiding 
the Hdolcscct!i wirh t·hrunic ill.ne~> to adulthDl)d. Clin 
Farn Pmct 2000;2: l-ll . 
i23J Lopez LM, ~~ewma'l S.l, Grimes DA, Nar:da K, Sclmhz 
KF. Irr11w:diatc: :::tMl of hom1onal contra.1;eptives for 
conlra((';ptim.1. Ccchra.m: Ddl:aba.s~ Syst Rev 2008;2: 
CDOG6260. 
[24] Canobbio MM: Contraception for tile adok~;ccr.t ;md 
your;g adult witb congenital. hc~art disc:ase. Nurs Clm 
North Am 2.{)04;39:769-85. 
[251 Power J, French R, Cowa.."t F. Sut.{lermal impianmbk: 
(:ontracepb\le5 ver~u;; other forms of rev::.rsible 
contraceptives or other inplants a.~ effective .methods for 
preventing pregnancy. Cochrane Database Syst Rev 
20C'l;3:CD00l32li . 
[26] Pcriard D, Haesicr E, Ducrey N, voq der Weki N , 
1-Ia4zolai L Ven~us' l)lrQmooembo tic: dis.;:a.<.e hi 
adoles,:en:.~ . Rev lVkd Sui~se 20()6:2{51 ):3 18-22. 
[2 .. 7j Cheng L, GlJ!mczaglu AM, J;>iaggio G; E:wurm E, Van 
Look PFA. Interventions !ur emerg~n~~y contraception. 
Codmmc Database Syst Rev 200R;2:Cl.l(Hl1324. 
j28] Society rcr Adolesc:e m: Mcdlcinc. Depot 
medrm;:yprogesterone iiCetatc and hor!e minerai tki1sity 
in adolescent5. 'l'he black box warr1ing: A po~ition p<1per 
of the Sodcjy for Adolescent Mediclne. J Ado!esc 
H:.:a.lt.h 2006;39:296-301.. 
S:.tbmiued: Octt1ber 06, 2.0ll. R.evis!!d· Nvvt:mber lS, 
201 i. Accepted:· UeL-.ernher 01 .. 2:01 l , 
;: . 
